UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 167

Sortiert nach

NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients

Breast cancer research : BCR, 2018-10, Vol.20 (1), p.120-120, Article 120

2018

Volltextzugriff (PDF)

Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer

Scientific reports, 2021-12, Vol.11 (1), p.23463-23463, Article 23463

2021

Volltextzugriff (PDF)

Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers

Clinical cancer research, 2022-11, Vol.28 (21), p.4714-4723

2022

Volltextzugriff (PDF)

Polymorphisms in the TP53-MDM2-MDM4-axis in patients with rheumatoid arthritis

Gene, 2021-08, Vol.793, p.145747-145747, Article 145747

2021

Volltextzugriff (PDF)

Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian Cancer

JAMA oncology, 2022-11, Vol.8 (11), p.1579

2022

Volltextzugriff (PDF)

Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer

Breast cancer research : BCR, 2012-03, Vol.14 (2), p.R47-R47, Article R47

2012

Volltextzugriff (PDF)

MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk

BMC cancer, 2017-02, Vol.17 (1), p.97, Article 97

2017

Volltextzugriff (PDF)

Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer

NMR in biomedicine, 2012-09, Vol.25 (9), p.1033-1042

2012

Volltextzugriff (PDF)

APOBEC3A/B deletion polymorphism and endometrial cancer risk

Cancer medicine (Malden, MA), 2023-03, Vol.12 (6), p.6659-6667

2023

Volltextzugriff (PDF)

Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension

PloS one, 2012-06, Vol.7 (6), p.e38364

2012

Volltextzugriff (PDF)

Long-Term Follow-Up of the Intergroup Exemestane Study

Journal of clinical oncology, 2017-08, Vol.35 (22), p.2507-2514

2017

Volltextzugriff (PDF)

Constitutional Mosaic Epimutations - a hidden cause of cancer?

Cell Stress, 2019-03, Vol.3 (4), p.118-135

2019

Volltextzugriff (PDF)

Assessment of tumor suppressor promoter methylation in healthy individuals

Clinical epigenetics, 2020-08, Vol.12 (1), p.131-131, Article 131

2020

Volltextzugriff (PDF)

Impact of MDM2 promoter SNP55 (rs2870820) on risk of endometrial and ovarian cancer

Biomarkers, 2021-05, Vol.26 (4), p.302-308

2021

Volltextzugriff (PDF)

Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate

Oncotarget, 2016-05, Vol.7 (19), p.28637-28646

2016

Volltextzugriff (PDF)

The multitude of molecular analyses in cancer: the opening of Pandora’s box

Genome Biology, 2014-09, Vol.15 (9), p.447-447, Article 447

2014

Volltextzugriff (PDF)

MDM2 promoter SNP55 (rs2870820) affects risk of colon cancer but not breast-, lung-, or prostate cancer

Scientific reports, 2016-09, Vol.6 (1), p.33153, Article 33153

2016

Volltextzugriff (PDF)

Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer

JCO precision oncology, 2023-09, Vol.7, p.e2300338

2023

Volltextzugriff (PDF)

Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon

International journal of cancer, 2015-07, Vol.137 (1), p.96-103

2015

Volltextzugriff (PDF)

A Mitochondrial Target Sequence Polymorphism in Manganese Superoxide Dismutase Predicts Inferior Survival in Breast Cancer Patients Treated with Cyclophosphamide

Clinical cancer research, 2009-06, Vol.15 (12), p.4165-4173

2009

Volltextzugriff (PDF)

High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy

Breast cancer research and treatment, 2001-05, Vol.67 (2), p.111-116

2001

Volltextzugriff (PDF)

Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer

Genes chromosomes & cancer, 2006-11, Vol.45 (11), p.1033-1040

2006

Volltextzugriff (PDF)

Interpreting plasma estrogen levels in breast cancer: caution needed

Journal of clinical oncology, 2014-05, Vol.32 (14), p.1396-1400

2014

Volltextzugriff (PDF)

Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer

Journal of clinical oncology, 2016-05, Vol.34 (14), p.1580-1583

2016

Volltextzugriff (PDF)

1 – 25 von 167

Suche als RSS-Feed

Aktive Filter

ThemaTumors

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(162)
Mit Volltextzugriff
(152)

Publikationsform

Artikel
(166)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(136)
Humans
(134)
Life Sciences & Biomedicine
(131)
Female
(101)
Oncology
(85)
Breast Neoplasms - Drug Therapy
(68)
Biological And Medical Sciences
(45)
Middle Aged
(44)
Medical Sciences
(41)
Aged
(37)
Breast Cancer
(36)
Pharmacology. Drug Treatments
(35)
Antineoplastic Agents
(31)
Chemotherapy
(27)
Breast Neoplasms - Genetics
(26)
Aromatase Inhibitors
(25)
Adult
(24)
Antineoplastic Agents - Therapeutic Use
(22)
Breast Neoplasms - Metabolism
(21)
Breast Neoplasms - Pathology
(20)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients

Impact of the APOBEC3A/B deletion polymorphism on risk of ovarian cancer

Mutational Signature 3 Detected from Clinical Panel Sequencing is Associated with Responses to Olaparib in Breast and Ovarian Cancers

Polymorphisms in the TP53-MDM2-MDM4-axis in patients with rheumatoid arthritis

Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian Cancer

Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer

MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk

Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer

APOBEC3A/B deletion polymorphism and endometrial cancer risk

Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension

Long-Term Follow-Up of the Intergroup Exemestane Study

Constitutional Mosaic Epimutations - a hidden cause of cancer?

Assessment of tumor suppressor promoter methylation in healthy individuals

Impact of MDM2 promoter SNP55 (rs2870820) on risk of endometrial and ovarian cancer

Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate

The multitude of molecular analyses in cancer: the opening of Pandora’s box

MDM2 promoter SNP55 (rs2870820) affects risk of colon cancer but not breast-, lung-, or prostate cancer

Homologous Recombination Deficiency Across Subtypes of Primary Breast Cancer

Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon

A Mitochondrial Target Sequence Polymorphism in Manganese Superoxide Dismutase Predicts Inferior Survival in Breast Cancer Patients Treated with Cyclophosphamide

High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy

Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer

Population distribution and ancestry of the cancer protective MDM2 SNP285 (rs117039649)

Interpreting plasma estrogen levels in breast cancer: caution needed

Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer

Aktive Filter

Suchergebnisse filtern